Primary Hepatic Lymphoma: Role of Low-Dose Radiotherapy at a Single Institution with Genetic Characterization and Paired Literature Review

放射治疗 淋巴瘤 医学 肿瘤科 内科学
作者
Jennifer Ma,Rémy Daou,Josiane Bou Eid,Jisun Lee,B. Fregonese,Joe M El-Khoury,N. Ari Wijetunga,Harper Hubbeling,Kathryn R. Tringale,Emily S. Lebow,Reith Sarkar,Brandon S. Imber,Joachim Yahalom,Carla Hajj
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 11949-11950
标识
DOI:10.1182/blood-2022-162623
摘要

Purpose/Objective: Primary hepatic lymphomas (PHL) are an extremely rare form of non-Hodgkin Lymphoma (NHL) for which there are no established treatment guidelines, with available literature largely comprised of small case reports. Therefore, we evaluate our institutional experience treating PHL within the context of existing literature to better understand treatment modalities, role of radiotherapy (RT), and outcomes. Traditionally, radiotherapy for indolent lymphomas has involved treatment of up to 2400cGy in 12 fractions, however the use of low-dose radiotherapy of 400cGy in 1-2 fractions has been increasingly utilized. However to our knowledge, use of low-dose RT for liver lymphomas has not previously been reported in the literature. Materials/Methods: We conducted a single institutional retrospective analysis of all PHL patients (pts) diagnosed from 2000-2021 with a biopsy-proven liver lesion without other lymphomatous solid organ involvement, except for concurrently diagnosed splenic lymphomas. Subgroup analysis was performed for diffuse large B-cell lymphoma (DLBCL) and indolent lymphomas, which included marginal zone (MZL), follicular (FL), and low-grade B-cell lymphoma (BCL), NOS. Univariable (UVA) and multivariable analysis (MVA) for overall survival (OS) was performed using the Cox proportional hazards model. A literature review was also conducted using key words "liver", "lymphoma", and "treatment" to identify all available reported cases of PHL. An institutional targeted sequencing database was queried to identify patients with PHL of DLBCL histology. Results: We identified 30 PHL pts within the institutional cohort and 192 pts from comprehensive literature review. Sixteen patients were male (53%), and 25 (83%) were ECOG 0. Twenty five (83%) were Lugano Stage I, 3 (10%) were Stage III, and 2 (7%) were Stage IV. Six (20%) patients had bulky disease and 3 (10%) had nodal involvement. Systemic therapy was the most common treatment modality with 20 patients (67%), and 4 patients (13%) each received surgery, radiation and observation in our institutional cohort. In the paired literature review, 96 patients (50%) received systemic therapy, 69 (36%) underwent surgery, 10 (5%) received radiation and 11 (6%) underwent observation. Seventeen (57%) of patients were alive and 5 (17%) lost to follow-up within our institutional cohort, compared with 97 patients (51%) alive and 3 (2%) lost to follow-up. Median survival in our cohort was 6 years, compared with 2 years among the literature review cohort. Subgroup analysis of DLBCL included 15 pts (Table 1). On MVA for OS, only ECOG score (p=0.02) and Lugano stage (p=0.04) remained significant. Subgroup analysis of the indolent lymphoma group included 9 pts (Figure 1). On MVA for OS, only age remained significant. Six DLBCL patients with available targeted sequencing data were identified, with 4 mutations mutated more than once: TP53 (50%), MEF2B (33%), P2RY8 (33%), and IRF8 (33%). Pathway mapping of genetic mutations was notable for alterations in cell cycle pathway genes TP53 and ATM (17%). No other pathways had greater than one genetic alteration. Conclusion: PHLs are a rare subtype of NHL without clear treatment consensus. Primary hepatic DLBCL is predominantly treated with chemotherapy in both our institutional experience and as reported in the literature, with reasonable disease control. Importantly, indolent PHL patients in the institutional cohort have been treated with various modalities including low-dose radiotherapy, which appears to achieve comparable disease control. However radiotherapy was not utilized as a modality for indolent PHL within the literature review. Therefore, this is the first report of the use of low-dose radiotherapy for treatment of indolent liver lymphomas. Our RT data is limited by short follow-up duration of RT pts compared to pts who received chemotherapy, surgery or observation. However, our results are encouraging for the consideration of low-dose radiotherapy as a management option for appropriate patients with indolent PHL. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
天天快乐应助nkmenghan采纳,获得10
1秒前
乐乐应助CCCr采纳,获得10
1秒前
希望天下0贩的0应助wjx采纳,获得30
1秒前
上官若男应助周周采纳,获得10
2秒前
2秒前
2秒前
柔弱的马里奥完成签到,获得积分10
2秒前
爱听歌蘑菇完成签到,获得积分10
3秒前
3秒前
BL发布了新的文献求助10
5秒前
田様应助慕容松采纳,获得10
6秒前
李红玉发布了新的文献求助10
6秒前
panda发布了新的文献求助10
6秒前
金雪完成签到,获得积分10
6秒前
7秒前
CipherSage应助butter采纳,获得10
7秒前
8秒前
田様应助伶俐一曲采纳,获得10
8秒前
FashionBoy应助Monika采纳,获得10
8秒前
Zww发布了新的文献求助10
8秒前
lll完成签到,获得积分10
9秒前
王者归来发布了新的文献求助200
9秒前
nkmenghan完成签到,获得积分10
9秒前
9秒前
9秒前
哈桑士完成签到,获得积分10
10秒前
10秒前
11秒前
成就的白羊完成签到,获得积分10
12秒前
CCCr发布了新的文献求助10
13秒前
Rondab应助轻松的冷雪采纳,获得30
13秒前
栗子完成签到 ,获得积分10
13秒前
13秒前
Moshiqi完成签到,获得积分10
14秒前
lll发布了新的文献求助10
14秒前
cqmuluo完成签到 ,获得积分10
16秒前
梦XING发布了新的文献求助10
17秒前
周周发布了新的文献求助10
17秒前
17秒前
孟双完成签到,获得积分10
17秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974856
求助须知:如何正确求助?哪些是违规求助? 3519400
关于积分的说明 11198085
捐赠科研通 3255563
什么是DOI,文献DOI怎么找? 1797860
邀请新用户注册赠送积分活动 877208
科研通“疑难数据库(出版商)”最低求助积分说明 806219